the aid library

LIST OPTIONS

Filter

2452

Sort by:

Direction:

Download (4285)

View PDF (2872)

Dermatological Preparations For The Tropics
recommended

Peter Bakker; Herman Woerdenbag; Vincent Gooskens; Ben Naafs, et al. (2012) C_WHO

A formulary of dermatological preparations and background information on therapeutic choices, production and dispensing. 2nd edition

Download (735)

View PDF (2145)

Nepal: National List of Essential Medicines, 2021
recommended

World Health Organisation (WHO) (2021) C_WHO

6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.

Download (393)

View PDF (674)

WHO Guidelines on tuberculosis infection prevention and control, 2019 update
recommended

World Health Organization (WHO) (2019) C_WHO

The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci... more

Download (248)

View PDF (195)

Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed
recommended

World Health Organization (WHO) (2021) C_WHO

Annex. This document is an update of a guidance published on 12 July 2021, after the review of new scientific evidence on transmission of SARS-CoV-2 variants of concern (VOC). It contains updated recommendations on the use of masks and respirators for health workers providing care to suspected or c... more

Download (114)

View PDF (145)

Handbook for the Management of Public Health Events in Air Transport

World Health Organization WHO (2016) C_WHO

Updated with information on Ebola virus disease and Middle East respiratory syndrome coronavirus A wide variety of health events ranging in severity may occur related to air transport, requiring different responses or, perhaps, no response at all. The target audience for this guidance document incl... more

Download (110)

View PDF (635)

The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients

Gyssens I. C., W. V. Kern, D. M. Livermore Haematologica (2013) C2

Haematologica has published European guidelines for empirical and targeted antibacterial therapy forfebrile neutropenic patients in the era of emerging resistance (ECIL-4). Indeed, collateral damage by broad-spectrum antibiotic therapy includes selection of multidrugresistant pathogens, and incr... more

Download (78)

View PDF (138)

Breastfeeding and COVID-19. FAQ

World Health Organization WHO (2020) C_WHO

Mothers and healthcare workers who support them have many questions and concerns about whether it is safe for mothers with confirmed or suspected COVID-19 to be close to and breastfeed their babies during the pandemic. To address their questions, WHO has released a list of Frequently asked question... more

Download (60)

View PDF (709)

Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study

Karagiannidis, C.; et al. (2020) C1

DOI:https://doi.org/10.1016/S2213-2600(20)30316-7 The Lancet Respiratory Medicine

Download (221)

View PDF (212)

Priority medical devices list for the COVID-19 response and associated technical specifications
recommended

World Health Organization WHO (2021) C_WHO

23 February 2021 This document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines. This includes: oxygen therapy, pulse oximeters, patient monitors, thermometers, infusion and suc... more

Download (153)

View PDF (119)

Avaliacao e manejo de sintomas prolongados de COVID-19

Ana Flor Hexel Cornely, João Gabriel Flôres da Rocha TelessaudeRS, Ministerio da Saude Brasil (2020) CC

Assessment and management of prolonged symptoms of COVID-19. Introdução Apesar de inicialmente ter sido considerada uma infecção aguda do sistema respiratório, atualmente sabe-se do comprometimento multissistêmico e protraído da COVID-19 em alguns indivíduos [1]. Segundo dados prelimi... more

Download (122)

View PDF (188)

National Guidelines for the Treatment of Malaria - 2019

South African Malaria Elimination Committee (SAMC) National Department of Health South Africa (2019) CC

These guidelines are based on the 3rd Edition of the WHO Guidelines (Published 2015) World Health Organization’s Guidelines for the treatment of malaria. Additional literature surveys have been undertaken. Factors that were considered in the choice of therapeutic options included effectiveness, sa... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (21)

View PDF (19)

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease

Abola, M. T. B.; Golledge, J.; Miyata, T. et al. Journal of Atherosclerosis and Thrombosis (2020) CC

Peripheral artery disease (PAD) is the most underdiagnosed, underestimated and undertreated of the atherosclerotic vascular diseases despite its poor prognosis. There may be racial or contextual differences in the Asia-Pacific region as to epidemiology, availability of diagnostic and therapeutic mod... more

Download (19)

View PDF (89)

Global action plan for the prevention and control of noncommunicable diseases 2013-2020 WHO

World Health Organization (WHO) World Health Organization (WHO) (2013) C_WHO

The Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020 by the World Health Organization (WHO) outlines a comprehensive strategy to address the global rise in noncommunicable diseases (NCDs), including cardiovascular diseases, cancer, chronic respiratory diseases,... more

Download (20)

View PDF (25)

Invisible numbers; The true extent of noncommunicable diseases and what to do about them 2022

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

Noncommunicable diseases (NCDs) – chief among them, cardiovascular diseases (heart disease and stroke), cancer, diabetes and chronic respiratory diseases – along with mental health, cause nearly three quarters of deaths in the world. Their drivers are social, environmental, commercial and geneti... more

Download (15)

View PDF (15)

Report - Invisible numbers: the true extent of noncommunicable diseases and what to do about them

World Health Organization (WHO) World Health Organization (WHO) (2022) C_WHO

Download (17)

View PDF (24)

WHO package of essential noncommunicable (PEN) disease interventions for primary health care

World Health Organization (WHO) World Health Organization (WHO) (2020) C_WHO

The "WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care" provides a set of cost-effective, evidence-based interventions to address noncommunicable diseases (NCDs) such as cardiovascular diseases, diabetes, chronic respiratory diseases, and cancers. Designed ... more

Download (22)

View PDF (80)

Proposed Strategies to Improve Adult Asthma Management in Egypt: Expert Review and Recommendations

Hosny, H.; Madkour, A.; Hantera, M.; et al. (2022) CC2

Several challenges face asthma management in Egypt, including the high percentage of uncontrolled patients, inadequate compliance, and overuse of short-acting beta-agonists (SABAs) leading to increased asthma-related morbidity and mortality. In this regard, the recent Global Initiative for Asthma (G... more

Download (24)

View PDF (14)

Silica-associated lung disease: An old-world exposure in modern industries

Barnes, H.; Goh, N. S. L.; Leong, T. L.; Hoy, R. Official Journal of the Asian Pacific Society of Respirology (2019) CC2

Silicosis is not a new disease; the impact of silica dust on respiratory function was observed by Hippocrates in 430 B.C. and in the 16th century by Agricol. In 1713, Rammazini described silicotic nodules in post-mortems of stone cutters presenting with respiratory symptoms. In the mid-late 1800s,... more

Download (23)

View PDF (14)

The burden of severe asthma in sub-Saharan Africa: Findings from the African Severe Asthma Project

Kirenga, B.J.; Chakaya, J.; Yimer, G. et al. Journal of Allergy and Clinical Immunology: Global (2024) CC

Severe asthma is associated with high morbidity, mortality, and health care utilization, but its burden in Africa is unknown. This article wants to determine the burden (prevalence, mortality, and activity and work impairment) of severe asthma in 3 countries in East Africa: Uganda, Kenya, and Ethio... more

Dermatological Preparations For The Tropics recommended

Nepal: National List of Essential Medicines, 2021 recommended

WHO Guidelines on tuberculosis infection prevention and control, 2019 update recommended

Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed recommended

Priority medical devices list for the COVID-19 response and associated technical specifications recommended

Dermatological Preparations For The Tropics
recommended

Nepal: National List of Essential Medicines, 2021
recommended

WHO Guidelines on tuberculosis infection prevention and control, 2019 update
recommended

Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed
recommended

Priority medical devices list for the COVID-19 response and associated technical specifications
recommended